Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 112-118 |
| Number of pages | 7 |
| Journal | Cancer Epidemiology |
| Volume | 54 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2018 |
Fingerprint
Cite this
Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. / Marchioni, Michele; Harmouch, SS; Nazzani, S; Bandini, Marco; Preisser, F; Tian, Z; Kapoor, A; Cindolo, L; Briganti, A; Shariat, SF; Schips, L; Karakiewicz, PI.
In: Cancer Epidemiology, Vol. 54, No. 6, 2018, p. 112-118.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma
AU - Marchioni, Michele
AU - Harmouch, SS
AU - Nazzani, S
AU - Bandini, Marco
AU - Preisser, F
AU - Tian, Z
AU - Kapoor, A
AU - Cindolo, L
AU - Briganti, A
AU - Shariat, SF
AU - Schips, L
AU - Karakiewicz, PI
PY - 2018
Y1 - 2018
N2 - Aim: To test the effect of African-American race on cancer specific mortality (CSM) in clear cell metastatic renal cell carcinoma (ccmRCC) and non-ccmRCC. Patients and methods: Within Surveillance, Epidemiology and End Results registry (2001–2014), we identified patients with ccmRCC and non-ccmRCC. We relied on propensity score (PS) matching to reduce the effect of inherent differences between African-American vs. Caucasian patients. After PS matching that included access to cytoreductive nephrectomy (CNT), cumulative incidence, competing-risks regression (CRR) models and landmark analyses tested the effect of race on CSM. Results: Before PS matching, African-American patients accounted for 7.0 and 24.5% of respectively ccmRCC (N = 6742) and non-ccmRCC patients (N = 766). After PS matching, African-American patients accounted for 22.3 and 33.5% of respectively ccmRCC (N = 2050) and non-ccmRCC (N = 391) matched cohorts. In multivariable CRR models focusing on ccmRCC, higher CSM was recorded in African-Americans (HR:1.27, p < 0.001). Conversely, in non-ccmRCC, lower CSM was recorded in African-Americans (HR:0.54, p < 0.001). Landmark analyses rejected the hypothesis of immortal time bias. Conclusion: African-Americans experienced higher CSM in ccmRCC. Conversely, African-Americans experienced lower CSM, when diagnosed with non-ccmRCC. These differences are independent of access to CNT and warrant further study since they may have an impact on efficacy or access to systemic therapies. © 2018 Elsevier Ltd
AB - Aim: To test the effect of African-American race on cancer specific mortality (CSM) in clear cell metastatic renal cell carcinoma (ccmRCC) and non-ccmRCC. Patients and methods: Within Surveillance, Epidemiology and End Results registry (2001–2014), we identified patients with ccmRCC and non-ccmRCC. We relied on propensity score (PS) matching to reduce the effect of inherent differences between African-American vs. Caucasian patients. After PS matching that included access to cytoreductive nephrectomy (CNT), cumulative incidence, competing-risks regression (CRR) models and landmark analyses tested the effect of race on CSM. Results: Before PS matching, African-American patients accounted for 7.0 and 24.5% of respectively ccmRCC (N = 6742) and non-ccmRCC patients (N = 766). After PS matching, African-American patients accounted for 22.3 and 33.5% of respectively ccmRCC (N = 2050) and non-ccmRCC (N = 391) matched cohorts. In multivariable CRR models focusing on ccmRCC, higher CSM was recorded in African-Americans (HR:1.27, p < 0.001). Conversely, in non-ccmRCC, lower CSM was recorded in African-Americans (HR:0.54, p < 0.001). Landmark analyses rejected the hypothesis of immortal time bias. Conclusion: African-Americans experienced higher CSM in ccmRCC. Conversely, African-Americans experienced lower CSM, when diagnosed with non-ccmRCC. These differences are independent of access to CNT and warrant further study since they may have an impact on efficacy or access to systemic therapies. © 2018 Elsevier Ltd
U2 - 10.1016/j.canep.2018.04.006
DO - 10.1016/j.canep.2018.04.006
M3 - Article
VL - 54
SP - 112
EP - 118
JO - Cancer Epidemiology
JF - Cancer Epidemiology
SN - 1877-7821
IS - 6
ER -